<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133781</url>
  </required_header>
  <id_info>
    <org_study_id>SU-17218- 2009</org_study_id>
    <secondary_id>2U19AI057229-06</secondary_id>
    <nct_id>NCT02133781</nct_id>
  </id_info>
  <brief_title>B-cell Immunity to Influenza (SLVP017)- Year 1, 2009</brief_title>
  <official_title>U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 1, 2009</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory study using a strategy that has not been previously employed to
      investigate the effects of age and vaccine type on specific kinds of immune responses to
      licensed, seasonal 2009-2010 influenza vaccines in children and adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted in healthy male and female volunteers. 8-17 year-old identical
      twins will be randomly assigned to receive a single administration of the 2009-2010
      formulation of either seasonal trivalent inactivated influenza vaccine (TIV) or live,
      attenuated influenza vaccine (LAIV). Twins within a pair will receive different vaccines.
      18-30 year-old and 70-100 year-old subjects will receive a single administration of the
      2009-2010 formulation of TIV. Blood samples to conduct the assays will be taken at
      pre-immunization, Day 7-8 and Day 28 post immunization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants From Each Arm Who Received Influenza Vaccine</measure>
    <time_frame>Day 0 to 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Adverse Events</measure>
    <time_frame>Day 0 to 28 post-immunization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To Investigate the Effects of Age and Vaccine Type on B-cell Responses to Influenza Vaccine</measure>
    <time_frame>Day 0 to 28</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Age 8-17 years (identical twins )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 18-30 years (non-twins)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be receive Fluzone® 2009-2010 Formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age &gt;70 years (non-twins)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone® 2009-2010 Formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® 2009-2010 Formula</intervention_name>
    <description>This vaccine is given intramuscularly</description>
    <arm_group_label>Age 8-17 years (identical twins )</arm_group_label>
    <arm_group_label>Age 18-30 years (non-twins)</arm_group_label>
    <arm_group_label>Age &gt;70 years (non-twins)</arm_group_label>
    <other_name>Trivalent inactivated influenza vaccine (TIV)</other_name>
    <other_name>FDA-licensed seasonal influenza vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist® 2009-2010 Formula</intervention_name>
    <description>This vaccine is given intranasally</description>
    <arm_group_label>Age 8-17 years (identical twins )</arm_group_label>
    <other_name>Live, attenuated influenza vaccine (LAIV)</other_name>
    <other_name>FDA-licensed seasonal influenza vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy, ambulatory children 8-17 year-old twins, adults 18-30 years old
             (non-twin) or 70-100 year-old elderly non-twin adults.

          -  Willing to complete the informed consent process.

          -  Availability for follow-up for the planned duration of the study at least 28 days
             after immunization.

          -  Acceptable medical history by medical history and vital signs.

        Exclusion Criteria:

          -  Prior off-study vaccination with the current seasonal TIV or LAIV in Fall 2009

          -  Allergy to egg or egg products, or to vaccine components, including gentamicin,
             gelatin, arginine or MSG (for LAIV only), or thimerosal (TIV multidose vials only).

          -  Life-threatening reactions to previous influenza vaccinations

          -  Asthma or history of wheezing (for volunteers randomized to LAIV)

          -  Active systemic or serious concurrent illness, including febrile illness on the day of
             vaccination

          -  History of immunodeficiency (including HIV infection)

          -  Known or suspected impairment of immunologic function, including, but not limited to,
             clinically significant liver disease, diabetes mellitus treated with insulin, moderate
             to severe renal disease, or any other chronic disorder which, in the opinion of the
             investigator, might jeopardize volunteer safety or compliance with the protocol.

          -  Blood pressure &gt;150 systolic or &gt;95 diastolic at first study visit

          -  Hospitalization in the past year for congestive heart failure or emphysema.

          -  Chronic Hepatitis B or C.

          -  Recent or current use of immunosuppressive medication, including systemic
             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in
             all groups; inhaled steroid use is not permissible except for non-LAIV Group only).
             Use of oral steroids (&lt;20 mg prednisone-equivalent/day) may be acceptable for
             volunteers 70-100 yrs of age after review by the investigator.

          -  Participants in close contact with anyone who has a severely weakened immune system
             should not receive LAIV

          -  Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
             such as breast cancer or prostate cancer with recurrence in the past year, and any
             hematologic cancer such as leukemia).

          -  Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
             of the investigator, might jeopardize volunteer safety or compliance with the
             protocol.

          -  History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
             medical follow up or hospitalization during the preceding year

          -  Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be
             reviewed by investigator to determine if this would affect the volunteer's safety.

          -  Receipt of blood or blood products within the past 6 months

          -  Medical or psychiatric condition or occupational responsibilities that preclude
             participant compliance with the protocol

          -  Inactivated vaccine 14 days prior to vaccination

          -  Live, attenuated vaccine within 60 days of vaccination

          -  History of Guillain-Barré Syndrome

          -  Pregnant or lactating woman

          -  Use of investigational agents within 30 days prior to enrollment

          -  Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment

          -  Any condition which, in the opinion of the investigator, might interfere with
             volunteer safety, study objectives or the ability of the participant to understand or
             comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Dekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry B Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaosong He, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford LPCH Vaccine Program</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://vaccines.stanford.edu/clinical_trials.html</url>
    <description>Stanford LPCH Vaccine Program Clinical Trials Website</description>
  </link>
  <reference>
    <citation>He XS, Sasaki S, Narvaez CF, Zhang C, Liu H, Woo JC, Kemble GW, Dekker CL, Davis MM, Greenberg HB. Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods. 2011 Feb 28;365(1-2):67-75. doi: 10.1016/j.jim.2010.12.008. Epub 2010 Dec 21.</citation>
    <PMID>21182843</PMID>
  </reference>
  <reference>
    <citation>Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, Nishtala M, Wrammert J, Smith K, James JA, Dekker CL, Davis MM, Wilson PC, Greenberg HB, He XS. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011 Aug;121(8):3109-19. doi: 10.1172/JCI57834. Epub 2011 Jul 25.</citation>
    <PMID>21785218</PMID>
  </reference>
  <reference>
    <citation>He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis. 2013 Jan 15;207(2):288-96. doi: 10.1093/infdis/jis664. Epub 2012 Oct 29.</citation>
    <PMID>23107783</PMID>
  </reference>
  <reference>
    <citation>Jiang N, He J, Weinstein JA, Penland L, Sasaki S, He XS, Dekker CL, Zheng NY, Huang M, Sullivan M, Wilson PC, Greenberg HB, Davis MM, Fisher DS, Quake SR. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med. 2013 Feb 6;5(171):171ra19. doi: 10.1126/scitranslmed.3004794. Erratum in: Sci Transl Med. 2013 Jul 10;5(193):193er8.</citation>
    <PMID>23390249</PMID>
  </reference>
  <reference>
    <citation>Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, Shen-Orr S, Dekker CL, Swan GE, Butte AJ, Maecker HT, Davis MM. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015 Jan 15;160(1-2):37-47. doi: 10.1016/j.cell.2014.12.020.</citation>
    <PMID>25594173</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <results_first_submitted>January 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Cornelia L. Dekker</investigator_full_name>
    <investigator_title>Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Inactivated influenza vaccine</keyword>
  <keyword>Live, attenuated influenza vaccine</keyword>
  <keyword>Child identical twins</keyword>
  <keyword>Young and elderly adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Age 8-17 Years (Identical Twins )</title>
          <description>Participants will be randomized to receive either Fluzone® 2009-2010 Formula or Flumist® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly
Flumist® 2009-2010 Formula: This vaccine is given intranasally</description>
        </group>
        <group group_id="P2">
          <title>Age 18-30 Years (Non-twins)</title>
          <description>Participants will be receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="P3">
          <title>Age &gt; 70 Years (Non-twins)</title>
          <description>Participants will receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age 8-17 Years (Identical Twins )</title>
          <description>Participants will be randomized to receive either Fluzone® 2009-2010 Formula or Flumist® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly
Flumist® 2009-2010 Formula: This vaccine is given intranasally</description>
        </group>
        <group group_id="B2">
          <title>Age 18-30 Years (Non-twins)</title>
          <description>Participants will be receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="B3">
          <title>Age &gt; 70 Years (Non-twins)</title>
          <description>Participants will receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants From Each Arm Who Received Influenza Vaccine</title>
        <time_frame>Day 0 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Age 8-17 Years (Identical Twins )</title>
            <description>Participants will be randomized to receive either Fluzone® 2009-2010 Formula or Flumist® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly
Flumist® 2009-2010 Formula: This vaccine is given intranasally</description>
          </group>
          <group group_id="O2">
            <title>Age 18-30 Years (Non-twins)</title>
            <description>Participants will be receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Age &gt; 70 Years (Non-twins)</title>
            <description>Participants will receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants From Each Arm Who Received Influenza Vaccine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Adverse Events</title>
        <time_frame>Day 0 to 28 post-immunization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Age 8-17 Years (Identical Twins )</title>
            <description>Participants will be randomized to receive either Fluzone® 2009-2010 Formula or Flumist® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly
Flumist® 2009-2010 Formula: This vaccine is given intranasally</description>
          </group>
          <group group_id="O2">
            <title>Age 18-30 Years (Non-twins)</title>
            <description>Participants will be receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Age &gt; 70 Years (Non-twins)</title>
            <description>Participants will receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Investigate the Effects of Age and Vaccine Type on B-cell Responses to Influenza Vaccine</title>
        <time_frame>Day 0 to 28</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 28 of study participation</time_frame>
      <desc>Clinical Assessment performed at each visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Age 8-17 Years (Identical Twins )</title>
          <description>Participants will be randomized to receive either Fluzone® 2009-2010 Formula or Flumist® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly
Flumist® 2009-2010 Formula: This vaccine is given intranasally</description>
        </group>
        <group group_id="E2">
          <title>Age 18-30 Years (Non-twins)</title>
          <description>Participants will be receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="E3">
          <title>Age &gt; 70 Years (Non-twins)</title>
          <description>Participants will receive Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula: This vaccine is given intramuscularly</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cornelia Dekker</name_or_title>
      <organization>Stanford University School of Medicine, Dept. of Pediatrics</organization>
      <phone>650-724-4437</phone>
      <email>cdekker@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

